Background: Extending contraceptive implant duration of use increases accessibility
include etonogestrel (ENG)-releasing devises, including Implanon and Nexplanon (Merck, Kenilworth, NJ, USA) and levonorgestrel (LNG)-releasing devices, including the Sino-Implant II (Dahua Pharmaceutical, Shanghai, China) and Jadelle (Bayer, Berlin, Germany). 12, 13 The only difference between the two ENG implants is that Nexplanon contains a radiopaque dye used to locate the device in the event that it cannot be palpated. The key aspects of product information for each of these devices is included in Table 1 .
Pharmacokinetic studies provide information about the serum levels exhibited throughout use of contraceptive implants as well as what levels are required to inhibit ovulation. Prior work indicates that ovulation is suppressed at serum ENG levels greater than 90 pg/mL. 14 McNicholas et al. 15 found that median ENG levels at the end of 3 years of use of the implant are beyond this value at 207.7 pg/mL (range 63.8-802.6 pg/mL). Median serum ENG levels remain high at 166.1 pg/mL (range 25-470.5 pg/mL) at 4 years of use and 153.0 pg/mL (range 72.1-538.8 pg/mL) at 5 years of use. 15 Furthermore, this study failed to show a difference in median serum ENG levels across body mass index (BMI) groups, including obese women, at the end of the fifth year of implant use. 15 However, women may exhibit wide ranges of ENG, with some values below 90 pg/mL, as McNicholas found in 23 participants (written communication, July 2017).
Among women using the LNG implant, variations in serum LNG levels exist. Sivin et al. 16 measured serum LNG concentrations among women extending duration. Pregnancies were identified in five women using the Jadelle LNG implant beyond 5 years. In all women, the serum LNG levels fell to or below 180 pg/mL, indicating that this may represent a threshold below which contraceptive efficacy cannot be guaranteed. Further analysis revealed that study site, body weight and ponderal index, and duration of use were the most important variables affecting serum LNG levels. 16 Importantly, the pharmacokinetic data on ENG and LNG have revealed that serum concentrations between participants and even within the same participant over multiple collections vary widely. We searched published studies among PubMed and EMBASE.
To locate articles, we used the following search terms for devices, developed together with a Health Science Librarian: "levonorgestrel", "norplant", "Jadelle", "etonogestrel", "Implanon", "Nexplanon" and "sino implant," as well as search terms for pregnancy outcomes (to assess T A B L E 1 Description of devices. contraceptive failure) and study designs including clinical trials or cohort studies (full search strategy available recorded in File S1).
The title and abstract from each article was independently eval- Reviewers abstracted the following information from the remaining articles: study title, authors, publication year, funding source, study design, population size, duration of extended use, type of implant, and number of contraceptive failures. The findings from each study were summarized and synthesized narratively; we did not calculate summary measures of association.
Using the United States Preventative Services Task Force (USPSTF)
guidelines, each article's study quality was rated as "poor," "fair," or "good". 19 This rating was based on methodological quality as assessed by the reviewers along the following domains: assembly of appropriate comparison groups (including adequate description and execution of randomization in RCTs and assessment of potential confounders in cohort studies such as participant age); maintenance of comparable groups and participant attrition during the study; and description of how pregnancy was assessed. Additionally, quality of data analysis and interpretation was assessed according to whether adjustments were performed for confounders, and whether contraceptive efficacy was measured cumulatively or analyzed separately among women beyond approved duration.
| RESULTS
We identified 2951 citations and selected 38 articles for full-text screening ( Fig. 1) . Thirty-two studies were excluded because they did not meet inclusion or exclusion criteria (File S2). We included six published studies in this systematic review, resulting in a total of 1075 women who self-selected extended duration of their contraceptive implant in a number of countries, including Brazil, Chile, Dominican Republic, Hungary, Thailand, Turkey, Zimbabwe, USA, and China 15, 16, [20] [21] [22] [23] (Table 2) .
We did not identify any studies that met the inclusion criteria for our primary question, comparing women who continued use of an implant after the approved duration with women who initiated a new implant after completing use through the approved duration.
All six studies were noncomparative cohort analyses assessing pregnancy rates during extended duration of implant use. Five studies evaluated the ENG implant (Implanon), and one evaluated the LNG implant, Jadelle. No published studies evaluated the Sino-Implant II.
No studies separately evaluated Nexplanon; however, this device has the same dose of ENG and pharmacokinetic properties as Implanon and is assumed to behave similarly. Two studies were sponsored by the manufacturer of the single-rod ENG implant. One study was published in Chinese and a translator was used to extract data. 21 Three studies separately evaluated contraceptive failure over the time frame of extended duration, 15, 16, 20 while the other three studies reported on cumulative pregnancy rates over the total time period of implant use (i.e. approved duration plus extended duration).
One publication represents interim analysis of an ongoing clinical trial-a large parent study of long-acting reversible contraception in St Louis, USA. 15 Those who consented to extending duration of their implants were followed and results of data collected during extension T A B L E 2 (Continued) completed 4 years of use and there were no reported pregnancies. 21 Two noncomparative cohort studies evaluated women with 1 year of extended use of the ENG implant. Women who were breastfeeding or recently using another method of contraception were excluded.
Sample sizes were small for women completing the fourth year of implant use (n=47 and n=151). No pregnancies were reported in either of these studies. 22, 23 We identified a multicenter pharmacokinetic study investigating extended duration of the LNG implant. Jadelle implants were inserted in 199 women across multiple sites over 7 years. The participants underwent regular blood draws to assess serum LNG levels. Over the course of the study, five women became pregnant: two in the fifth year and three in the seventh year. All five women had serum LNG levels that fell to or below 180 pg/mL and the two women who conceived in the fifth year demonstrated consistently low LNG levels in the three measurements prior to pregnancy. 16 
| DISCUSSION
This systematic review identified six studies published from 1996 to 2017 that met inclusion and exclusion criteria. Five studies evaluated the ENG implant (Implanon) and one evaluated the LNG implant (Jadelle). There were no studies of the Nexplanon or Sino-Implant II.
One study was an RCT, however randomization was to contraceptive method, not duration; the remaining five studies were prospective cohort studies. Three studies separately analyzed contraceptive efficacy among women beyond currently approved duration. All studies were of poor to fair quality by USPTF grading.
These studies enrolled a total of 1075 women and assessed con- 
